64x Bio
64x Bio accelerates cell & gene therapy with high throughput cell line design for biomanufacturing.
64x Bio accelerates cell & gene therapy with high throughput cell line design for biomanufacturing.
64x Bio, founded with a mission to revolutionize cell and gene therapy, focuses on accelerating the discovery and optimization of mammalian cell lines for biomanufacturing. Their core vision is to transform the future of therapeutics by leveraging a high throughput discovery and screening platform integrated with computational design. This innovative approach aims to generate highly optimized cell lines, particularly for the production of viral vectors used in cell and gene therapies, thereby enhancing the efficiency and scalability of therapeutic manufacturing processes.
Notable figures affiliated with 64x Bio include experts in genome engineering and computational biology, though specific names are not provided. The company has attracted significant interest from investors in the biotech sector due to its groundbreaking technology. Key achievements include the development of their proprietary platform that significantly speeds up cell line discovery and optimization. The overall impact of 64x Bio lies in its potential to drastically improve the production and accessibility of next-generation therapeutics, positioning itself as a pivotal player in the biomanufacturing landscape.
Companies similar to 64x Bio include Synvivia, WhiteLab Genomics, Xcell Biosciences and CellChorus.
64x Bio was founded in 2017.
64x Bio's headquarters is located in San Francisco, CA, US.
64x Bio's most recent funding round was for $55M (USD) in January 2022.
As of Jan 19, 2022, 64x Bio has disclosed funding of $59.6M (USD). Undisclosed round amounts are excluded.
64x Bio has 30 employees as of Feb 4, 2024.
CellChorus
cellchorus.com
